<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756388</url>
  </required_header>
  <id_info>
    <org_study_id>39698</org_study_id>
    <nct_id>NCT04756388</nct_id>
  </id_info>
  <brief_title>Examining Strategy Monitoring and Remediation Training</brief_title>
  <acronym>E-SMART</acronym>
  <official_title>E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Executive Function Training is a cognitive training approach that specifically trains&#xD;
      executive functioning for people with schizophrenia-spectrum disorders. The current study&#xD;
      compares full executive function training to computerized training alone and to strategy&#xD;
      monitoring alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All interventions will involve 4 weeks of group treatment consisting of two 1-hour group&#xD;
      sessions per week and additional practice at home between sessions. The Executive Training&#xD;
      condition will consist of 50% of the session practicing computerized cognitive training&#xD;
      exercises, and 50% of the session developing cognitive strategies to use in the computerized&#xD;
      exercises. Participants are encouraged to complete 40 minutes of computerized training per&#xD;
      day, and complete strategy worksheets, at home between sessions. In Computerized Cognitive&#xD;
      Training only participants will spend the entire one-hour session practicing computerized&#xD;
      training exercises. Between sessions participants will be encouraged to practice the&#xD;
      computerized exercises at home for 40 minutes per day. There will be no strategy development&#xD;
      in this condition. In Strategy Development only participants will engage in cognitive&#xD;
      strategy discussions to develop new executive function strategies that can be used in daily&#xD;
      life. Between sessions, participants will be encouraged to practice their cognitive&#xD;
      strategies in their daily life and track their strategies using the strategy worksheet. There&#xD;
      will be no computerized cognitive training in this condition. All interventions will be&#xD;
      delivered virtually in the participant's home and group sessions will be conducted using the&#xD;
      online platform Zoom.&#xD;
&#xD;
      90 participants with schizophrenia-spectrum disorders will be recruited. Power analyses,&#xD;
      conducted with GPower, indicate that 90 participants (30 per treatment condition), accounting&#xD;
      for an upper limit of 25% attrition observed in my previous trials of ET, provides 80% power&#xD;
      to detect a medium effect size (cohen's f = 0.2) difference between conditions.&#xD;
&#xD;
      Primary and secondary outcomes will be examined using Linear Mixed Models on the&#xD;
      Intent-to-Treat sample with missing data interpolated using maximum likelihood estimation.&#xD;
      The primary endpoint is the 3-month follow-up assessment, and secondary endpoint of&#xD;
      post-treatment will also be examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive Computerized Cognitive Training only, Strategy Development only, or both (Executive Functioning Training; ET).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants will be informed that they will be randomized to one of three types of cognitive training, however, will have no idea what the conditions or the hypotheses. Outcome assessors will be blind to condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Levels of Functioning Scale</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>This is a measure of community functioning rated by the research assessor based on an interview</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cambridge Neuropsychological Test Automated Battery (CANTAB)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The CANTAB is a battery consisting of highly sensitive, precise and objective measures of cognitive function. It includes tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wide Range Achievement Test (WRAT)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The WRAT is an academic skills assessment which measures reading skills, math skills, spelling, and comprehension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire About the Process of Recovery (QPR)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The QPR was developed from service users' accounts of recovery from psychosis in collaboration with local service users. It asks people living with psychosis about aspects of recovery that are meaningful to them, and is strongly associated with general psychological wellbeing, quality of life and empowerment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The BPRS measures psychopathology and symptom severity and is sensitive to changes in symptom levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The Q-LES-Q is a sensitive measure of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysfunctional Attitudes Scale (DAS)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The DAS measures self-defeating attitudes theorized to underlie clinical depression and anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Core Schema Scale (BCSS)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The BCSS assesses four dimensions of self and other evaluation: negative-self, positive-self, negative-other, and positive-other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Self-Efficacy Scale (GSES)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The GSES assesses optimistic self-beliefs to cope with a variety of difficult demands in life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Failures Questionnaire (CFQ)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The CFQ was designed to measure perception, memory, and motor lapses in daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Cognition Scale (NCS)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The NCS measures &quot;the tendency for an individual to engage in and enjoy thinking.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Davos Assessment of Cognitive Biases (DACOBS)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The DAVOS measures cognitive biases and discriminates between schizophrenia spectrum patients and normal control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation and Pleasure Scale - Self-Report (MAP-SR)</measure>
    <time_frame>Change from Baseline to 12-Week Follow-up</time_frame>
    <description>The MAP-SR assesses the motivation and pleasure domains of negative symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Executive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Executive Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy Development only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Computerized Cognitive Training only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strategy Development</intervention_name>
    <description>Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.</description>
    <arm_group_label>Executive Training</arm_group_label>
    <arm_group_label>Strategy Development only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computerized Cognitive Training</intervention_name>
    <description>Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.</description>
    <arm_group_label>Computerized Cognitive Training only</arm_group_label>
    <arm_group_label>Executive Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The target population for this study are those who meet the criteria for schizophrenia&#xD;
        based on the DSM-V diagnosis. The inclusion criteria is anyone who meets the criteria of&#xD;
        schizophrenia, schizoaffective disorder or any other psychotic disorder, are also 18-65&#xD;
        years of age, know how to use a computer, are not abusing drugs or alcohol and can read and&#xD;
        speak English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria include anyone enrolled in a cognitive training program in the last 6&#xD;
        months, anyone with a neurological disease or neurological damage, medical illnesses that&#xD;
        can change neurocognitive function, medical history of head injury with loss of&#xD;
        consciousness and those with physical handicaps.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Best, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Best, PhD</last_name>
    <phone>416-208-4825</phone>
    <email>m.best@utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felicia Martins, HBSc (IPR)</last_name>
    <email>bestlabadmin.utsc@utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Toronto Scarborough</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1C 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Best, PhD</last_name>
      <phone>416-208-4825</phone>
      <email>m.best@utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Felicia Martins, HBSc (IPR)</last_name>
      <email>bestlabadmin.utsc@utoronto.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Best, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cantab.com</url>
    <description>CANTAB Virtual Assessment</description>
  </link>
  <link>
    <url>https://books.google.ca/books?id=amQXtAEACAAJ</url>
    <description>WRAT-5: Wide Range Achievement Test Professional Manual</description>
  </link>
  <reference>
    <citation>Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005 Sep;66(9):1122-9.</citation>
    <PMID>16187769</PMID>
  </reference>
  <reference>
    <citation>Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.</citation>
    <PMID>15753237</PMID>
  </reference>
  <reference>
    <citation>Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007 Sep;33(5):1225-37. Epub 2007 Jan 4.</citation>
    <PMID>17204532</PMID>
  </reference>
  <reference>
    <citation>Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA; CATIE Investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007 Mar;164(3):428-36.</citation>
    <PMID>17329467</PMID>
  </reference>
  <reference>
    <citation>Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010 Jul;67(7):674-82. doi: 10.1001/archgenpsychiatry.2010.63. Epub 2010 May 3.</citation>
    <PMID>20439824</PMID>
  </reference>
  <reference>
    <citation>Subramaniam K, Luks TL, Fisher M, Simpson GV, Nagarajan S, Vinogradov S. Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron. 2012 Feb 23;73(4):842-53. doi: 10.1016/j.neuron.2011.12.024.</citation>
    <PMID>22365555</PMID>
  </reference>
  <reference>
    <citation>Best MW, Milanovic M, Iftene F, Bowie CR. A Randomized Controlled Trial of Executive Functioning Training Compared With Perceptual Training for Schizophrenia Spectrum Disorders: Effects on Neurophysiology, Neurocognition, and Functioning. Am J Psychiatry. 2019 Apr 1;176(4):297-306. doi: 10.1176/appi.ajp.2018.18070849. Epub 2019 Mar 8.</citation>
    <PMID>30845819</PMID>
  </reference>
  <reference>
    <citation>Best MW, Gale D, Tran T, Haque MK, Bowie CR. Brief executive function training for individuals with severe mental illness: Effects on EEG synchronization and executive functioning. Schizophr Res. 2019 Jan;203:32-40. doi: 10.1016/j.schres.2017.08.052. Epub 2017 Sep 19.</citation>
    <PMID>28931460</PMID>
  </reference>
  <reference>
    <citation>Wykes T, Spaulding WD. Thinking about the future cognitive remediation therapy--what works and could we do better? Schizophr Bull. 2011 Sep;37 Suppl 2:S80-90. doi: 10.1093/schbul/sbr064. Review.</citation>
    <PMID>21860051</PMID>
  </reference>
  <reference>
    <citation>Best MW, Bowie CR. A review of cognitive remediation approaches for schizophrenia: from top-down to bottom-up, brain training to psychotherapy. Expert Rev Neurother. 2017 Jul;17(7):713-723. doi: 10.1080/14737175.2017.1331128. Epub 2017 May 24. Review.</citation>
    <PMID>28511562</PMID>
  </reference>
  <reference>
    <citation>Ruse SA, Harvey PD, Davis VG, Atkins AS, Fox KH, Keefe RS. Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance. Schizophr Res Cogn. 2014 Mar;1(1):e21-e26.</citation>
    <PMID>25083416</PMID>
  </reference>
  <reference>
    <citation>Neil ST, Kilbride M, Pitt L, Nothard S, Welford M, Sellwood W, Morrison AP. The questionnaire about the process of recovery (QPR): A measurement tool developed in collaboration with service users. Psychosis. 2009; 1(2): 145-155.</citation>
  </reference>
  <reference>
    <citation>Faustman WO, Overall JE. (1999). Brief Psychiatric Rating Scale. In M. E. Maruish (Ed.), The use of psychological testing for treatment planning and outcomes assessment (p. 791-830). Lawrence Erlbaum Associates Publishers.</citation>
  </reference>
  <reference>
    <citation>Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.</citation>
    <PMID>8290681</PMID>
  </reference>
  <reference>
    <citation>Weissman AN, Beck AT. Development and validation of the dysfunctional Attitude Scale: A preliminary investigation. Paper presented at the Association for the Advancement of Behavior Therapy; Chicago. 1978.</citation>
  </reference>
  <reference>
    <citation>Fowler D, Freeman D, Smith B, Kuipers E, Bebbington P, Bashforth H, Coker S, Hodgekins J, Gracie A, Dunn G, Garety P. The Brief Core Schema Scales (BCSS): psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. Psychol Med. 2006 Jun;36(6):749-59. Epub 2006 Mar 27.</citation>
    <PMID>16563204</PMID>
  </reference>
  <reference>
    <citation>Schwarzer R, Jerusalem M. (1995). Generalized Self-Efficacy scale. In J. Weinman, S. Wright, &amp; M. Johnston, Measures in health psychology: A user's portfolio. Causal and control beliefs (pp. 35-37). Windsor, UK: NFER-NELSON.</citation>
  </reference>
  <reference>
    <citation>Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982 Feb;21(1):1-16.</citation>
    <PMID>7126941</PMID>
  </reference>
  <reference>
    <citation>Cacioppo JT, Petty RE. The need for cognition. Journal of Personality and Social Psychology. 1982; 42: 116-131.</citation>
  </reference>
  <reference>
    <citation>van der Gaag M, Sch√ºtz C, Ten Napel A, Landa Y, Delespaul P, Bak M, Tschacher W, de Hert M. Development of the Davos assessment of cognitive biases scale (DACOBS). Schizophr Res. 2013 Mar;144(1-3):63-71. doi: 10.1016/j.schres.2012.12.010. Epub 2013 Jan 15.</citation>
    <PMID>23332365</PMID>
  </reference>
  <reference>
    <citation>Llerena K, Park SG, McCarthy JM, Couture SM, Bennett ME, Blanchard JJ. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry. 2013 Jul;54(5):568-74. doi: 10.1016/j.comppsych.2012.12.001. Epub 2013 Jan 22.</citation>
    <PMID>23351831</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Michael Best</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>psychosis</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>cognitive remediation</keyword>
  <keyword>executive functioning</keyword>
  <keyword>strategy monitoring</keyword>
  <keyword>computerized practice</keyword>
  <keyword>cognitive training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT04756388/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

